

From stockgenwatch@suri.co.jp Sun Apr 18 02:06:40 MET 1999
Received: from mesquite.ein.cz (negdo@mesquite.ein.cz [212.24.139.67])
	by eivind.imm.dtu.dk (8.8.6 (PHNE_14041)/8.8.6) with ESMTP id CAA01289
	for <fnielsen@eivind.imm.dtu.dk>; Sun, 18 Apr 1999 02:06:38 +0200 (METDST)
From: stockgenwatch@suri.co.jp
Received: from mesquite.ein.cz (mut-53-0427.direct.ca [216.66.133.123]) by mesquite.ein.cz (8.8.5/8.6.10) with SMTP id CAA00992; Sun, 18 Apr 1999 02:05:02 +0200
To: newupdate@wilmington.net
Message-ID: <198754623569.GAA87641@wilmington.net>
Date: Sat, 17 Apr 99 16:53:04 EST
Subject: RE: BIOTECH BARGAIN!
Status: RO
X-Status: 

Company: Endovasc Ltd., Inc.
Symbol:  E N D V
Price:   9/16 ($.56/share)

Whisperstocks indicates persistent
and credible rumours of a $4/share buyout
of ENDV by a major pharamceutical.

The April issue of the British Biotechnology
Journal, Oxford, England states "scientists
at Glaxo Wellcome have proven the efficacy of Endovasc's PGE-1 and
have submitted to management
a multi-million dollar joint venture proposal".
 
ENDV is recommended as an immediate and "STRONG BUY". 






